Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Open-Label, Multicenter Phase III Study Comparing the Efficacy and Safety of Intensity-Modulated Proton Therapy Versus Intensity-Modulated Photon Radiation Therapy for Diffuse Intrinsic Pontine Glioma (imPro-DIPG-01)

NCT07869524 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.

NCT NCT07869524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07869524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Open-Label, Multicenter Phase III Study Comparing the Efficacy and Safety of Intensity-Modulated Proton Therapy Versus Intensity-Modulated Photon Radiation Therapy for Diffuse Intrinsic Pontine Glioma (imPro-DIPG-01)
Lead sponsor
Shandong Cancer Hospital and Institute
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
December 31, 2031
Enrollment
142 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine gliomas (dipg)